.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC02_Fluorouracil.Fluorouracil_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC02_Fluorouracil.Fluorouracil_1| name: | Fluorouracil_1 |
| ATC code: | L01BC02_1 | route: | intravenous |
| n-compartments | 2 |
Fluorouracil (5-FU) is an antimetabolite chemotherapy drug for cancers such as colorectal and breast cancer, disrupting DNA synthesis by inhibiting thymidylate synthase. Approved and commonly used intravenously.
Pharmacokinetics in adults receiving continuous IV infusion.
Ismael, G, et al., & Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet. Oncology 13(9) 869–878. DOI:10.1016/S1470-2045(12)70329-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884505
Rietveld, PCS, et al., & Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 176 116820–None. DOI:10.1016/j.biopha.2024.116820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38810398
Batey, MA, et al., & Boddy, AV (2002). Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European journal of cancer (Oxford, England : 1990) 38(8) 1081–1089. DOI:10.1016/s0959-8049(02)00024-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12008196